Navigation Links
Watching, Reading and Listening: A New Way to Interact with Patient Information
Date:4/24/2012

may increase your ability to fight HIV. Your healthcare professional will work with you to find the right combination of HIV medicines
  • It is important that you remain under the care of your healthcare professional during treatment with PREZISTA®
  • PREZISTA® does not cure HIV infection or AIDS and you may continue to experience illnesses associated with HIV-1 infection, including opportunistic infections. You should remain under the care of a doctor when using PREZISTA®.Please read Important Safety Information below, and talk to your healthcare professional to learn if PREZISTA® is right for you.Important Safety InformationWhat is the most important information I should know about PREZISTA?

  • PREZISTA® can interact with other medicines and cause serious side effects. See "Who should not take PREZISTA®?"
  • PREZISTA® may cause liver problems. Some people taking PREZISTA®, together with Norvir® (ritonavir), have developed liver problems which may be life-threatening. Your healthcare professional should do blood tests before and during your combination treatment with PREZISTA®. If you have chronic hepatitis B or C infection, your healthcare professional should check your blood tests more often because you have an increased chance of developing liver problems
  • Tell your healthcare professional if you have any of these signs and symptoms of liver problems: dark (tea-colored) urine, yellowing of your skin or whites of your eyes, pale-colored stools (bowel movements), nausea, vomiting, pain or tenderness on your right side below your ribs, or loss of appetite
  • PREZISTA® may cause a severe or life-threatening skin reaction or rash. Sometimes these skin reactions and skin rashes can become severe and require treatment in a hospital. You should call your healthcare professional immediately if you develop a rash. However, stop taking
    '/>"/>

  • SOURCE Janssen Therapeutics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Transitions Optical and VSP Vision Care Partner with Bess the Book Bus to Bring Healthy Vision and a Love of Reading to Palmetto Elementary Students
    2. Bringing Pain Management to Africa: Spreading Relief Through Training
    3. TeleHealth Services and Reading Hospital and Medical Center Partner to Reach Technology-Driven Patient Education Goals
    4. Face Masks Offer Protection Against Spreading H1N1
    5. The CementBloc and Novartis Vaccines to Jointly Present Top Considerations in Interactive Selling at the 11th Annual iPharmaConnect
    6. Medco Study Finds Many Patients on Newer Oncology Treatments Are at Risk for Drug Interactions
    7. LodgeNet Interactive to Report Fourth Quarter and Full Year 2011 Results on February 22nd
    8. Study Finds No Drug-Drug Interaction Between Aggrenox® (aspirin/extended-release dipyridamole) 25mg/200mg Capsules and Omeprazole, a Widely Used PPI
    9. Centra Health and TeleHealth Services Partner to Launch Enterprise Interactive Patient Education for Patient Satisfaction and Safety
    10. Homestead of Sherman Uses AccuNurse Interactive Care to Improve Care and Service
    11. Ira Haimowitz, PhD, EVP, at The CementBloc, to Present on Best Practices in iPad Interactive Selling at 11th Annual ePharma Summit™
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... NEW YORK , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer ... the board of directors of Advaxis, Inc. ("Advaxis" or ... the board has breached its fiduciary duties to shareholders. ... published on an investing website reporting that Advaxis had ...
    (Date:1/23/2015)... 2015  iMD Companies, Inc. (ICBU) has repositioned itself as a ... grab a foothold in the hydroponic, hemp and medical marijuana ... presence in the sector, and recently partnering with the Chippewa ... and medical marijuana, iMD is committing to bring its vision ...
    (Date:1/23/2015)... MONMOUTH JUNCTION, N.J. , Jan. 23, 2015 ... immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber ... surgery patients, announced the receipt of $385,642, net ... approved participant of the Technology Business Tax Certificate ...
    Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
    ... /PRNewswire/ -- Sirion Therapeutics,announced today that data on ... ST-602 (fenretinide), will be,presented at the 2007 annual ... Ophthalmology (ARVO) in Ft. Lauderdale, FL.,In addition to ... for ARVO attendees. , ST-601 (difluprednate) is currently ...
    ... 11:00 a.m. Eastern Time, LONDON, April 24, 2007 ... today announces,top-line results from its two Phase III ... The Company conducted two Phase,III double-blind, placebo-controlled studies ... placebo or 2 grams (1 gram twice,daily) of ...
    Cached Medicine Technology:Sirion Therapeutics Announces Clinical Data to be Presented at the,2007 Association for Research in Vision and Ophthalmology (ARVO),Annual Meeting 2Sirion Therapeutics Announces Clinical Data to be Presented at the,2007 Association for Research in Vision and Ophthalmology (ARVO),Annual Meeting 3Sirion Therapeutics Announces Clinical Data to be Presented at the,2007 Association for Research in Vision and Ophthalmology (ARVO),Annual Meeting 4Amarin Reports Top-Line Results of two Phase III Studies of,Miraxion in Huntington's Disease 2Amarin Reports Top-Line Results of two Phase III Studies of,Miraxion in Huntington's Disease 3Amarin Reports Top-Line Results of two Phase III Studies of,Miraxion in Huntington's Disease 4Amarin Reports Top-Line Results of two Phase III Studies of,Miraxion in Huntington's Disease 5
    (Date:1/22/2015)... 2015 Blue Cross and Blue Shield of ... what it means to “Live Fearless.” , The ... share their stories about how they or someone they know ... by living in the moment. By telling these types of ...
    (Date:1/22/2015)... The federal court overseeing thousands of vaginal mesh ... District of West Virginia has upheld a $2 million verdict ... trial. In an Order dated January 21st, the Court denied ... C.R. Bard had not proven a miscarriage of justice. (Cisson ...
    (Date:1/22/2015)... A new white paper by The Beryl ... the long-term care environment as well as provides recommendations ... paper, “The Power of Person-Centeredness in Long-Term Care: A ... the patient, resident and family experience in long-term care ...
    (Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post ... insurance policy . , Auto insurance quotes help many ... no longer necessary to call an agent or visit an ... on a single website: http://autocarinsurancebest.com/ . , Every business ...
    (Date:1/22/2015)... 22, 2015 Carinsurancesavings.biz has released a new ... and dismemberment insurance . , Purchasing an accidental death ... very advantageous. This type of rider provides benefits if the ... be considered a lesser form of life insurance. , ...
    Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
    ... Ga., Oct. 28 For those who think cranberries ... research revealed this week confirms that the crimson berry ... Leading scientists from throughout the country and abroad convened ... Institute Health Research Conference to review the latest ...
    ... and HAMBURG, Germany, Oct. 28 Zogenix, Inc. ... Pharmaceuticals GmbH ("Desitin"), a privately held, mid-sized German ... for European regulatory approval of SUMAVEL DosePro (sumatriptan ... successful completion of a European pivotal bioequivalence trial ...
    ... Fla., Oct. 28 Connectyx Technologies Holdings Group Inc. (Pink ... Manager (PHM), a revolutionary tool for the management of medical, ... Manager is an internet based, data storage and transfer platform ... information. It features secure storage and access to data ...
    ... ... Atlanta Snoring Institute, was recently featured in a prominent local newspaper article ... to prevent infection, especially during cold and flu season. Dr. Herman ... at the Atlanta Snoring Institute, a leading area center for relief of ...
    ... ... Hospital Readmission , ... Atlanta, Georgia (PRWEB) October 28, 2009 -- The IN Compass Health Hospitalist team, led ... team,s project "Indigent Diabetic Patient Follow-Up Care Program" at the BayCare Morton Plant Hospital. ...
    ... from an American Cancer Society (ACS) scientific advisory subcommittee ... should be minimized or eliminated whenever feasible, and calls ... the large number of chemicals to which the public ... an initiative to address ongoing and emerging issues related ...
    Cached Medicine News:Health News:Cranberries Provide Eight-Hour Health Protection 2Health News:Cranberries Provide Eight-Hour Health Protection 3Health News:Zogenix and Desitin Announce Filing for European Regulatory Approval of SUMAVEL(TM) DosePro(TM) 2Health News:Zogenix and Desitin Announce Filing for European Regulatory Approval of SUMAVEL(TM) DosePro(TM) 3Health News:Zogenix and Desitin Announce Filing for European Regulatory Approval of SUMAVEL(TM) DosePro(TM) 4Health News:Zogenix and Desitin Announce Filing for European Regulatory Approval of SUMAVEL(TM) DosePro(TM) 5Health News:Connectyx Announces the MedFlash Personal Health Manager 2Health News:Connectyx Announces the MedFlash Personal Health Manager 3Health News:Atlanta Snoring Institute Doctor Provides Expert Advice on Relief of Flu Symptoms and Prevention of Sinus Infection 2Health News:Atlanta Snoring Institute Doctor Provides Expert Advice on Relief of Flu Symptoms and Prevention of Sinus Infection 3Health News:Atlanta Snoring Institute Doctor Provides Expert Advice on Relief of Flu Symptoms and Prevention of Sinus Infection 4Health News:IN Compass Health's Hospitalist Team at Morton Plant Wins First BayCare Quality Award 2Health News:IN Compass Health's Hospitalist Team at Morton Plant Wins First BayCare Quality Award 3Health News:IN Compass Health's Hospitalist Team at Morton Plant Wins First BayCare Quality Award 4Health News:American Cancer Society calls for new strategies to monitor exposure to environmental carcinogens 2
    The PHOS method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of phosphorus in serum....
    For the quantitative in vitro determination of total and direct bilirubin in serum or plasma....
    For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum...
    For the quantitative in vitro determination of IgA in serum and plasma. This product is suitable for use on Hitachi 704, 705, 717, 902, 911 and 912....
    Medicine Products: